Patients with different types of cancer respond differently to treatment. The presence of an immune-suppressing protein in non-cancerous immune cells may predict this response. This was shown in a multi-center phase I study using an investigational immune therapy drug. The study, led by a Yale Cancer Center investigator, is described in the Nov. 27 edition of the journal iNature/i. The trial included patients with melanoma or cancers of the lung, kidney, colon, ...
Read More
No comments:
Post a Comment